MET and neoplasm: Yet in contradiction, comparative MET-dependent and MET-independent cell-based studies on tivantinib have also shown MET agnostic anti-tumor activity, posing that tivantinib may have an alternative inhibitory mechanism than an MET-selective one (Michieli and Di Nicolantonio, 2013; Basilico et al., 2013; Katayama et al., 2013; Fujino et al., 2019).